Kardiyovasküler Akademi Derneği Ulusal Kongresi 2022, Girne, Kıbrıs (Kktc), 16 - 20 Eylül 2022, ss.57, (Özet Bildiri)
Background: The Meta‐analysis Global Group in Chronic Heart Failure (MAGGIC) is a scoring system that is easy to use in outpatient or inpatient
settings and was developed to predict the survival of heart failure (HF) patients after hospitalization.
Aim: This study aims to determine the prognostic significance of MAGGIC risk score combined with electrocardiography (ECG) parameters in decompensated
patients with heart failure with reduced left ventricular ejection fraction (HFrEF) who were hospitalized for worsening HF.
Methods: A total of 562 HF patients with New York Heart Association (NYHA) II-IV functional class who were discharged after hospitalization for
decompensated HF between 2013 and 2018 in a single center were included. MAGGIC risk scores of all participating patients were calculated according
to baseline characteristics gathered using data from the initial hospitalization for HF. In addition, electrocardiographic findings of all patients
were examined.
Results: During the follow-up period (4.5±1.2 years) 177 patients died. MAGGIC scores were observed to be higher in non-survivors compared to
surviving patients (28.69±7.01 vs. 22.82±6.05, p<0.001). After a multivariate analysis, MAGGIC score (OR:1.090, p<0.001), development of cardiorenal
syndrome (OR:2.035, p<0.001), presence of left bundle branch block (LBBB) (OR:1.931, p<0.001), atrial fibrillation (AF) (OR:1.817, p<0.001),
and fragmented QRS (fQRS) (OR:1.671, p=0.002) on ECG were found to be independent predictors of mortality. While the MAGGIC score was
shown to predict mortality (AUC=0.739), its predictive power was improved when combined with AF (AUC=0.752), LBBB (AUC=0.745), and fQRS
(AUC=0.757) respectively, as well as in the combined final model (MAGGIC score, AF, LBBB, fQRS) (AUC=0.787).
Conclusions: Our findings showed that addition of electrocardiographic findings to the MAGGIC heart failure risk score has prognostic significance
in decompensated patients with HFrEF.